Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C15H23NO2 |
| Molecular Weight | 249.3486 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CNCC(C1=CC=C(O)C=C1)C2(O)CCCCC2
InChI
InChIKey=MMSWXJSQCAEDLK-UHFFFAOYSA-N
InChI=1S/C15H23NO2/c1-16-11-14(12-5-7-13(17)8-6-12)15(18)9-3-2-4-10-15/h5-8,14,16-18H,2-4,9-11H2,1H3
| Molecular Formula | C15H23NO2 |
| Molecular Weight | 249.3486 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
N,O-Didesmethylvenlafaxine is a metabolite of venlafaxine, an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class. In humans, venlafaxine is biotransformed for the most part by CYP2D6 and CYP2C19 isoenzymes to its major metabolite O-desmethylvenlafaxine, and in parallel to N-desmethylvenlafaxine and N,O-didesmethylvenlafaxine. It was shown, that CYP2D6 genotype influenced the O-demethylation whereas CYP2C19 influenced the N-demethylation of venlafaxine and its metabolites.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Reversible cardiac dysfunction after venlafaxine overdose and possible influence of genotype and metabolism. | 2016-09 |
|
| Influence of CYP2D6 genotype on the disposition of the enantiomers of venlafaxine and its major metabolites in postmortem femoral blood. | 2012-01-10 |
|
| High performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI) method for simultaneous determination of venlafaxine and its three metabolites in human plasma. | 2007-05-01 |
|
| Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting. | 2002-08 |
|
| Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. | 1999-08 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:23:48 GMT 2025
by
admin
on
Mon Mar 31 21:23:48 GMT 2025
|
| Record UNII |
DYW3W9739Y
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1175795
Created by
admin on Mon Mar 31 21:23:48 GMT 2025 , Edited by admin on Mon Mar 31 21:23:48 GMT 2025
|
PRIMARY | |||
|
135308-74-6
Created by
admin on Mon Mar 31 21:23:48 GMT 2025 , Edited by admin on Mon Mar 31 21:23:48 GMT 2025
|
PRIMARY | |||
|
3451347
Created by
admin on Mon Mar 31 21:23:48 GMT 2025 , Edited by admin on Mon Mar 31 21:23:48 GMT 2025
|
PRIMARY | |||
|
DTXSID10891441
Created by
admin on Mon Mar 31 21:23:48 GMT 2025 , Edited by admin on Mon Mar 31 21:23:48 GMT 2025
|
PRIMARY | |||
|
DYW3W9739Y
Created by
admin on Mon Mar 31 21:23:48 GMT 2025 , Edited by admin on Mon Mar 31 21:23:48 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE INACTIVE | |||
|
PARENT -> METABOLITE INACTIVE |
<5% (NODV and NODV-glucuronide);
Unit: percent of amount administered
IN-VIVO
URINE
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
